246 related articles for article (PubMed ID: 26480240)
1. Review of vorapaxar for the prevention of atherothrombotic events.
Wang A
Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
[TBL] [Abstract][Full Text] [Related]
2. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
3. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Lam S; Tran T
Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
[TBL] [Abstract][Full Text] [Related]
4. Vorapaxar in atherosclerotic disease management.
Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.
Perez-Rivera JA; Monedero-Campo J; Cieza-Borrella C; Ruiz-Perez P
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):339-350. PubMed ID: 28135897
[TBL] [Abstract][Full Text] [Related]
6. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
8. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
9. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
10. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.
Frampton JE
Drugs; 2015 May; 75(7):797-808. PubMed ID: 25895464
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
13. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
[TBL] [Abstract][Full Text] [Related]
14. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
15. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Moon JY; Franchi F; Rollini F; Angiolillo DJ
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
[TBL] [Abstract][Full Text] [Related]
16. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
18. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
[TBL] [Abstract][Full Text] [Related]
19. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
[TBL] [Abstract][Full Text] [Related]
20. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
Gryka RJ; Buckley LF; Anderson SM
Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
